Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Feasibility Study of Docetaxel and Nedaplatin for Recurrent Squamous Cell Carcinoma of the Uterine Cervix

YOH WATANABE, HIDEKATSU NAKAI, TOMOMARO ETOH, KAZUMI KANEMURA, ISAO TSUJI, AYAKO ISHIZU and HIROSHI HOSHIAI
Anticancer Research July 2008, 28 (4C) 2385-2388;
YOH WATANABE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: watanabe@med.kindai.ac.jp
HIDEKATSU NAKAI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMOMARO ETOH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUMI KANEMURA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ISAO TSUJI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AYAKO ISHIZU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI HOSHIAI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: To determine a new taxane plus platinum treatment regimen for squamous cell carcinoma of the uterine cervix (CSCC), a phase I feasibility study of docetaxel (DTX) plus nedaplatin (CDGP) combination therapy was conducted. Patients and Methods: Twenty consecutive patients were enrolled into the study. The starting dose of DTX/CDGP was 60 mg/m2 / 80 mg/m2, every 4 weeks for at least three courses and the dose was escalated to 70 mg/m2 / 100 mg/m2. DTX 60 mg/m2 / CDGP 100 mg/m2 was also evaluated as an extra dose level. Results: Dose-limiting toxicity was granulocytopenia and the maximum tolerated dose was determined as 70 mg/m2 / 100 mg/m2. All 20 patients had measurable disease and a partial response was achieved in 8 (40.0%) patients. Conclusion: DTX/CDGP therapy appears to be a tolerable regimen for cervical squamous cell carcinoma, even in patients previously treated by cisplatin concurrent chemoradiotherapy. The recommended doses of DTX and CDGP were determined to be 60 mg/m2 and 100 mg/m2, respectively.

  • Feasibility
  • cervical cancer
  • docetaxel
  • nedaplatin
  • chemotherapy

Footnotes

  • Received March 6, 2008.
  • Revision received May 16, 2008.
  • Accepted May 19, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (4C)
Anticancer Research
Vol. 28, Issue 4C
July-August 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Feasibility Study of Docetaxel and Nedaplatin for Recurrent Squamous Cell Carcinoma of the Uterine Cervix
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
16 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Feasibility Study of Docetaxel and Nedaplatin for Recurrent Squamous Cell Carcinoma of the Uterine Cervix
YOH WATANABE, HIDEKATSU NAKAI, TOMOMARO ETOH, KAZUMI KANEMURA, ISAO TSUJI, AYAKO ISHIZU, HIROSHI HOSHIAI
Anticancer Research Jul 2008, 28 (4C) 2385-2388;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Feasibility Study of Docetaxel and Nedaplatin for Recurrent Squamous Cell Carcinoma of the Uterine Cervix
YOH WATANABE, HIDEKATSU NAKAI, TOMOMARO ETOH, KAZUMI KANEMURA, ISAO TSUJI, AYAKO ISHIZU, HIROSHI HOSHIAI
Anticancer Research Jul 2008, 28 (4C) 2385-2388;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer
  • Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
  • Rare Upper Mediastinal Oligometastasis from Early Esophagogastric Adenocarcinoma: A Case Report
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire